Importantly, therapies such as GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors not only improve glycemic control but also lower circulating ceramides in patients with type 2 diabetes (Shalaby et al. 2025; Wretlind et al. 2023; Denimal et al. 2023). Here, GLP1R is linked to type 2 diabetes mellitus.